EBITDA sell-side analyst consensus figures
April 21, 2021
The consensus figures are based on analysts’ estimates recorded by the Company. The below consensus figures represent the aggregated expectations of sell-side analysts who, to the best of our knowledge, cover Aperam on a continuous basis.
The analysts listed below follow Aperam on their own initiative and Aperam is not responsible for their views.
Adj. EBITDA consensus estimates
|Period||Number of sell-side|
|Adj. EBITDA consensus average|
|Q1 2021||11||Average: EUR 147 million|
Range: EUR 125 million – 169 million
* Data as of April 21, 2021
The sell-side consensus is compiled from updated and maintained forecasts from the analysts named below:
- Alphavalue (does not provide quarterly estimates)
- Bank of America Merrill Lynch
- Credit Suisse
- Degroof Petercam
- Deutsche Bank
- Exane BNP Paribas
- JP Morgan
- Morgan Stanley
- Oddo BHF
- Societe Generale
The consensus estimate is based on estimates, forecasts and predictions made by third party financial analysts and can only be seen as a consensus view on Aperam’s results from an outside perspective. Aperam does not accept any responsibility for the quality or accuracy of forecasts or estimates. This web page may contain forward-looking statements based on current assumptions and forecasts made by Aperam or third parties. Various known and unknown risks, uncertainties and other factors could lead to material differences between Aperam’s actual future results, financial situation, development or performance, and the estimates given here. These factors include those discussed in Aperam’s periodic reports available on www.aperam.com, section Investors & Shareholders.